Effect of deferoxamin on stroke

Effect of deferoxamine on hemorrhagic transformation of middle cerebral artery stroke

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013111915444N2

Enrollment

Registered

2014-11-12

Start date

2014-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: stroke. Condition 2: intracerebral haemorrhage. Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries Sequelae of intracerebral haemorrhage

Interventions

Intervention 1: Intervention group: Deferoxamin, vial 500 mg, dose of 40 mg/kg/day, venous transfusion for 3 days. Intervention 2: control group: without intervention.

Treatment - Drugs

Intervention group: Deferoxamin, vial 500 mg, dose of 40 mg/kg/day, venous transfusion for 3 days

control group: without intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Acute ischemic stroke in middle cerebral artery territory. Exclusion criteria: renal failure; hemorrhagic stroke; stroke in other arterial territory; coagulopathies and history of anticoagulant drugs; anemia

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serrum ferritin. Timepoint: First and fourth day of addmission. Method of measurement: Microgram per litre with ferritin test kit.	—

Secondary

Measure	Time frame
Hemorrhagic transformation. Timepoint: Fourth and seventh day. Method of measurement: CT scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Maghuli

Ahvaz Jondishapur University of Medical Sciences

ahmad.m1368@yahoo.com; a.maghuli@ajums.ac.ir+98 61 1336 1984

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026